Hannen, Laura Erika Maria
Toprak, Betül
Weimann, Jessica
Mahmoodi, Bahara
Fluschnik, Nina
Schrage, Benedikt
Roedl, Kevin
Söffker, Gerold
Kluge, Stefan
Issleib, Malte
Blankenberg, Stefan
Kirchhof, Paulus
Clemmensen, Peter
Sinning, Christoph
Zengin-Sahm, Elvin
Becher, Peter Moritz http://orcid.org/0000-0003-1221-7015
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 30 May 2022
Accepted: 10 August 2022
First Online: 17 August 2022
Declarations
:
: Dr. Becher was partially supported by the German Research Foundation (Grant number BE 7424/2-1). Dr. Schrage received funding from the German Research Foundation and the Else Kröner-Fresenius-Stiftung, and speakers fees from Astra Zeneca, outside from the submitted work. Dr. Toprak receives funding for a research project by the German Foundation of Heart Research outside the submitted work. Dr. Kluge received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from Astra, Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. Dr. Blankenberg reports grants from Abbott Diagnostics, Siemens, Singulex, grants and personal fees from Bayer, Thermofisher, personal fees from Novartis, outside the submitted work; and payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events, support for attending meetings and travel from Abbott, AstraZeneca, Bayer, Amgen, Medtronic, Pfizer, Siemens and Thermofisher, all outside the submitted work. Dr. Kirchhof was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Dr. Clemmensen reports personal fees from Abbott, Acarix, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Evolva, Fibrex, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Regado, Sanofi, Searle, and Servier, all outside the submitted work. Dr. Sinning received fees from AstraZeneca and Johnson&Johnson, all outside the submitted work. Dr. Zengin-Sahm received fees from AstraZeneca, all outside the submitted work. Dr. Hannen, Dr. Fluschnik, Dr. Issleib, Dr. Roedl, Dr. Söffker, Mrs. Mahmoodi, Mrs. Weimann have no COI to declare.